KEYNOTE-052: 5-Yr Update of First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.